← All trials
NCT04935177
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 14, 2021
- Primary completion
- Jul 30, 2023
- Completion date
- Jul 30, 2023
- First posted
- Jun 22, 2021
- Last posted
- Nov 16, 2021
- Enrollment
- 64
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- HansaBioMedLead sponsor
- HansaBioMedStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.